ArticleClinical rheumatology2026
The Treatment-Related Burnout Scale for Rheumatic Diseases: Development and Preliminary Validation.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION/
objectivesTo develop and validate the Treatment-Related Burnout Scale for Rheumatic Diseases and to evaluate treatment-related burnout levels and associated factors in patients with rheumatologic diseases.
methodsThis methodological and descriptive study was conducted with two independent patient samples with rheumatologic diseases. In the first stage, a draft scale was developed through literature review and expert consultation. Content validity was assessed using the Davis technique. Exploratory factor analysis and reliability analyses were performed in a sample of 260 participants. In the second stage, confirmatory factor analysis and regression analyses were conducted in an independent sample of 248 participants. Internal consistency was evaluated using Cronbach's alpha and composite reliability, while convergent validity was assessed using average variance extracted.
resultsFollowing item analysis and exploratory factor analysis, the final scale consisted of 28 items and four subdimensions: Emotional and Cognitive Exhaustion, Treatment-Related Exhaustion, Disease-Related Functional Burden, and Healthcare System and Treatment Process Burden. The four-factor structure explained 63.30% of the total variance. Confirmatory factor analysis indicated an acceptable, although not optimal, model fit (χ
conclusionThe Treatment-Related Burnout Scale for Rheumatic Diseases provides preliminary evidence of validity and reliability as a multidimensional instrument for assessing treatment-related burnout in patients with rheumatologic diseases. The scale may contribute to clinical assessment and future research by providing a comprehensive evaluation of psychosocial burden related to long-term treatment processes. Key Points • The Treatment-Related Burnout Scale for Rheumatic Diseases (TBS-RD) is a newly developed 28-item instrument designed to assess treatment-related burnout in emotional, cognitive, functional, and healthcare system-related domains. •Exploratory and confirmatory factor analyses confirmed a four-factor structure. The total scale showed a Cronbach's alpha of 0.966, with composite reliabilities ranging from 0.81 to 0.95 for the subscales. • Patients with rheumatological diseases experienced moderate treatment-related burnout, with emotional and cognitive exhaustion being the most significant factors. • Gender was significantly associated with emotional and cognitive exhaustion, highlighting the importance of individualized, psychosocially informed clinical management.
Indexed as
Identifiers
42479264What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.